New Test for Early Osteoarthritis Diagnosis to Improve Clinical Decision-Making

As the population ages, the prevalence of osteoarthritis (OA) continues to rise. Typically, osteoarthritis is diagnosed in its later stages when cartilage degradation is advanced, making it challenging to differentiate from other forms of arthritis. Accurate differentiation of primary osteoarthritis from other arthritic conditions is essential for effective treatment strategies. Now, researchers have developed a new diagnostic test utilizing a dual-biomarker algorithm to aid in the diagnosis of osteoarthritis.

Developed and tested by CD Diagnostics (Claymont, DE, USA), the new test analyzes two markers found in the synovial fluid of patients' joints. The test employs a dual-biomarker algorithm to inform osteoarthritis diagnosis. In patients with confirmed primary osteoarthritis in the study, synovial fluid showed elevated levels of cartilage oligomeric matrix protein. However, this biomarker alone was not sufficient to differentiate primary osteoarthritis from other inflammatory conditions that also result in cartilage damage. To address this, the team also assessed levels of cartilage oligomeric matrix protein and interleukin-8. Using the ratio of these two markers, they developed an algorithm that was validated in differentiating osteoarthritis from inflammatory arthritis in 171 knee synovial fluid specimens.

The results, published in the Journal of Orthopedic Research, showed that the osteoarthritis algorithm achieved clinical sensitivity and specificity of 87.0% and 88.9%, respectively. This is the first report of a biomarker test capable of distinguishing primary osteoarthritis from inflammatory arthritis with a high degree of accuracy. This innovative dual-biomarker algorithm, based on synovial fluid analysis, represents a significant advancement in the accurate diagnosis of osteoarthritis, particularly in distinguishing it from inflammatory arthritis. The approach holds great promise for improving clinical decision-making and patient outcomes, addressing a critical gap in arthritis diagnosis.

“This study addresses an unmet need for objective diagnosis of osteoarthritis to improve clinical decision-making and patient outcomes,” said corresponding author Daniel Keter, BA, of CD Diagnostics, A Division of Zimmer Biomet.

Related Links:
CD Diagnostics

Visit expo >

Gold Member

Blood Gas Analyzer

GEM Premier 7000 with iQM3

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

New

Epstein-Barr Virus Assay

Panther Fusion EBV Quant Assay

New

Human Chorionic Gonadotropin Test

Humasis hCG Combo